Our work
In England, over 300,000 people are diagnosed with cancer every year. While diagnostics and treatments have developed greatly over the past decade, new treatments remain expensive. There is a need for tools that enable better disease characterisation and stratification.
Tumouroids are created using collagen as the basic matrix protein. They combine compartments that mimic both the cancer mass and the surrounding microenvironment of solid tumours that contain fibroblasts and endothelial cells.
Using plastic compression to expel excess fluid makes tumouroids one of the few cancer models to have measurable and tuneable tissue stiffness - a key characteristic of solid cancers.
Our aim is to develop this as a platform for personalised medicine - to predict the response to drugs of each patient with cancer.
Latest feature

Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells
We recently optimised tumouroid manufacture using cells from patients with renal cancers. We used them to test whether they respond to clinical drugs.
Our experts
The team works across the Division of Surgery & Interventional Science and with national and international collaborators.

Professor of Cancer Nanotechnology (Group Head)

Professor of Bioengineering (Group Head)

Professor of Photochemistry and Photobiology

Professor of Advanced Therapeutics

Associate Professor

Professor of Urology

Associate Lecturer

Senior Lecturer

Dean, Faculty of Medical Sciences

Lecturer in Medical Innovation and Enterprise

Dr Hazel Welch
Senior Teaching Fellow

Senior Research Fellow
Divisonal Research Team
- Tayebeh Azimi
- Deniz Bakkalci
- Kalliopi (Kelly) Bokea
- Ebrahim Abdal
- Salma Galal
- Auxtine Micalet
- Sami Znati
- Andrea Balukova
- Anuja Upadhyay
- Tan Xu
- Bow Chaipanichkul
- Daniel De Silva
Funding / Partnerships
UK Research Councils (EPSRC), NIHR, Industry, and Charities, including:
- The Royal Free Charity
- St Peter's Trust
- Biss-Davis Charitable Foundation
- SCAT Bone Cancer Fund.
Select publications
Stamati K., Tran M.G.B., Emberton M., Loizidou M., Cheema U., et al. (2022). Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells. J. Cell Commun. Signal.
Azimi T., Loizidou M., Dwek M.V. (2020). Cancer cells grown in 3D under fluid flow exhibit an aggressive phenotype and reduced responsiveness to the anti-cancer treatment doxorubicin. Sci Rep. 2020 Jul 21;10(1):12020.
Pape J., Stamati K., Loizidou M., Emberton M., Cheema U., et al. (2020). Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma. Br J Cancer 2020 Jul 9.
Stamati K., Tran, M.G.B., Emberton, M., Cheema, U., Loizidou, M., et al. (2020). The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic 3D renal tumouroids. J Tissue Eng. May 18. eCollection 2020.
Mohammad-Hadi, L., Yaghini, E., MacRobert, A., and Loizidou, M. (2020). Synergy between photodynamic therapy and dactinomycin chemotherapy in 2D and 3D cultures of ovarian cancer cells. Int J Mol BioSci, 2020 Apr 30;21(9):3203.
Related courses

Nanotechnology & Regenerative Medicine MSc
This renowned cross-disciplinary master's programme gives you a robust scientific understanding in the fields of nanotechnology and regenerative medicine.

Medical Innovation & Enterprise BSc / MSci
Get medical science and business skills. We'll equip you with the entrepreneurial mindset needed to create companies and identify emerging medical opportunities that can benefit patients and society.